ANI Pharmaceuticals, Inc. (ANIP) 의 후행 P/E는 21.0, 선행 P/E 8.7. 후행 이익수익률은 4.77%, 선행 이익수익률 11.56%. PEG 0.05 (Peter Lynch 저평가 ≤1.0). 그레이엄 넘버는 $47.91.
이 페이지에서 입증된 기준:
SharesGrow 종합 점수: 70/100 3/7 개 기준 통과.
| Year | P/E (TTM) | PEG 비율 | P/B 비율 | P/S 비율 | 배당 수익률 |
|---|---|---|---|---|---|
| 2016 | 176.4 | -2.36 | 4.09 | 5.39 | - |
| 2017 | -691.6 | 5.43 | 4.26 | 4.21 | - |
| 2018 | 33.9 | -0.02 | 2.66 | 2.61 | - |
| 2019 | 119.8 | -1.94 | 3.43 | 3.54 | - |
| 2020 | -15.4 | 0.03 | 1.78 | 1.67 | - |
| 2021 | -13.6 | -0.17 | 1.62 | 2.69 | 0.03% |
| 2022 | -13.7 | 1.33 | 1.93 | 2.07 | 0.25% |
| 2023 | 52.9 | -0.40 | 2.17 | 2.04 | 0.16% |
| 2024 | -57.7 | 0.28 | 2.49 | 1.74 | 0.15% |
| 2025 | 20.2 | -0.05 | 2.93 | 1.79 | 0.07% |
| Year | EPS (희석) | 매출 | 순이익 | 순이익률 |
|---|---|---|---|---|
| 2016 | $0.34 | $128.62M | $3.93M | 3.1% |
| 2017 | $-0.09 | $176.84M | $-1.08M | -0.6% |
| 2018 | $1.32 | $201.58M | $15.49M | 7.7% |
| 2019 | $0.50 | $206.55M | $6.09M | 3% |
| 2020 | $-1.88 | $208.48M | $-22.55M | -10.8% |
| 2021 | $-3.38 | $216.14M | $-42.6M | -19.7% |
| 2022 | $-2.95 | $316.39M | $-47.9M | -15.1% |
| 2023 | $0.94 | $486.82M | $18.78M | 3.9% |
| 2024 | $-0.87 | $614.38M | $-18.52M | -3% |
| 2025 | $3.32 | $883.37M | $78.34M | 8.9% |
| Year | EPS (평균) | EPS 범위 | 매출 (평균) | 매출 범위 | 애널리스트 수 |
|---|---|---|---|---|---|
| 2026 | $9.05 | $8.87 – $9.17 | $1.09B | $1.07B – $1.11B | 5 |
| 2027 | $10.57 | $9.71 – $11.67 | $1.21B | $1.14B – $1.26B | 4 |
| 2028 | $12.46 | $11.78 – $12.92 | $1.3B | $1.29B – $1.31B | 3 |
| 2029 | $12.69 | $11.99 – $13.16 | $1.37B | $1.32B – $1.41B | 2 |
| 2030 | $13.45 | $12.71 – $13.95 | $1.5B | $1.43B – $1.54B | 2 |
